Despite these cuts, the FDA should be able to stay above a "trigger" level that would prevent it from collecting fees from the pharma industry and deprive it of approximately half of its annual funding, according to The Washington Post.| BioSpace
Get expert career advice, insights on job trends and quarterly biopharma job market reports. Expect us in your inbox every Thursday.| BioSpace
2024 was a tough year for the biopharma industry, with several companies cutting hundreds or even thousands of employees. Follow along as BioSpace tracks job cuts and restructuring initiatives throughout 2025.| BioSpace